Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer
机构：[1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[2]Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[3]Shandong Provincial Hospital, Jinan, China[4]Sichuan Cancer Hospital, Chengdu, Sichuan, China四川省肿瘤医院[5]Department of Gastric Surgery, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China浙江省肿瘤医院[6]Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, China[7]Chinese PLA General Hospital, Beijing, Beijing, China[8]Liaoning Provincial Tumor Hospital, Shenyang, China[9]Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China[10]Department of Digestive Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shannxi, China[11]Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China[12]Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical, Beijing, China[13]The Third Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室外三科河北医科大学第四医院[14]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China[15]Xiangya Hospital, Central South University, Changsha, Hunan, China[16]Lanzhou University Second Hospital, Lanzhou, China[17]Renmin Hospital of Wuhan University, Wuhan, China
第一作者机构：[1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
推荐引用方式(GB/T 7714)：
Han Liang,Xiaona Wang,Liang Shang,et al.Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(3_SUPPL):TPS428-TPS428.doi:10.1200/JCO.2024.42.3_suppl.TPS428.
APA：
Han Liang,Xiaona Wang,Liang Shang,Xiaodong Chen,Xiangdong Cheng...&Yanliang Liu.(2024).Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.JOURNAL OF CLINICAL ONCOLOGY,42,(3_SUPPL)
MLA：
Han Liang,et al."Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer".JOURNAL OF CLINICAL ONCOLOGY 42..3_SUPPL(2024):TPS428-TPS428
医学